The U.S. stock resurgence basically relies on the optimism that a COVID-19 vaccine will soon be found. Investors are still waiting for clinical data on their ability to work.
A UBS analysis stated that 40% of the gains of the market ever since May could go for the vaccines that can protect us against the new virus. Let us remind you that it has already killed more than 960,000 worldwide. The economy was stopped for a few months.
All the global efforts done to find a vaccine are finally coming through. Many companies, such as Pfizer Inc and Moderna Inc, are doing late-stage data on trials. If the results are disappointing, this could shake the markets, which have started to become even more problematic. There’s also uncertainty when it comes to the 3rd of November U.S. presidential election.
Walter Todd, chief investment officer at Greenwood Capital in South Carolina, stated: “The anticipation is that this stuff is going to work. So any news to the contrary could be a risk to the market.”
The vaccines that are in development could actually blunt the negative market impact. More than six vaccines are currently in works – in the late-stages – from the 30 that are presently being tested in humans.
Liz Young, director of market strategy at BNY Mellon Investment Management, said: “We are setting ourselves up for success in the sense of if you throw enough spaghetti at the wall, hopefully at least one noodle sticks.”
Just earlier this month, AstraZeneca Plc had put on hold the global trials of one of the leading vaccine candidates, when one of the participants got really sick. All of the trials have resumed in South Africa, Britain, and Brazil, and, as of now, U.S. is still on hold.